News

Transcend Therapeutics Achieves Significant Results in PTSD Study

Transcend Therapeutics Achieves Significant Results in PTSD Study

Transcend Therapeutics Reports Positive Outcomes from Clinical Study

Transcend Therapeutics has recently announced that it has successfully met the primary endpoint in its clinical trial evaluating TSND-201 for the treatment of PTSD. This development marks a significant milestone for the company and offers hope for effective treatment of this complex mental health condition.

Key Findings and Study Design of IMPACT-1

In the IMPACT-1 Phase 2 study, TSND-201 showed a statistically significant improvement on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), with a noteworthy placebo-adjusted reduction of -9.64 points on Day 64 (p = 0.011). Notably, rapid improvements were also observed, with a significant -8.00 points reduction noted as early as Day 10, showcasing the efficacy of TSND-201.

Impact on Secondary Endpoints

Alongside the primary endpoint metrics, TSND-201 demonstrated robust benefits across several secondary endpoints by Day 64, including a greater than 50% improvement in PTSD symptoms for 57.1% of participants receiving TSND-201 compared to only 19.2% in the placebo group. Additionally, the remission rate was significantly higher in the treatment group, with 32.1% reaching below the CAPS-5 threshold for PTSD diagnosis.

Safety and Tolerability of TSND-201

As for safety, TSND-201 was generally well tolerated among participants. Adverse effects were mostly transient, occurring on the dosing day and resolving promptly. Common side effects included headache, decreased appetite, and mild nausea, underscoring a favorable safety profile aligned with its non-hallucinogenic pharmacological properties.

Expert Commentary

The encouraging results from the study have drawn attention within the medical community. Blake Mandell, the Co-Founder and CEO of Transcend Therapeutics, expressed optimism regarding the potential of TSND-201, stating the results highlight its role as a rapid-acting treatment for patients suffering from PTSD. He indicated plans to engage with the FDA to discuss a Phase 3 program that could further validate these promising outcomes.

Future Directions for Transcend Therapeutics

Transcend Therapeutics, established in 2021, is committed to developing groundbreaking treatments for neuropsychiatric conditions like PTSD. They aim to offer solutions for those who have not found relief with existing psychiatric medications. Through its innovative approach, Transcend has collectively contributed to multiple FDA approvals and amassed significant financial backing.

Potential of TSND-201

Given its unique pharmacological profile as a neuroplastogen, TSND-201 is not only being developed for PTSD but also for other central nervous system conditions. This investigational medication represents a novel class of treatment that opens new avenues for patients who have historically faced limited options in treating their mental health challenges.

Understanding PTSD and Its Treatment Landscape

Post-Traumatic Stress Disorder (PTSD) is a serious mental health condition stemming from exposure to traumatic events. It can severely disrupt the lives of those affected, leading to symptoms like flashbacks, anxiety, and disturbances in mood. Current treatment options remain inadequate for many, emphasizing the urgent need for innovative therapies like TSND-201, which promises a refreshing alternative in the medical toolkit.

Frequently Asked Questions

What is TSND-201?

TSND-201 is an investigational medication developed by Transcend Therapeutics, aimed at treating PTSD through rapid-acting mechanisms with a non-hallucinogenic profile.

What were the results of the Phase 2 study?

The Phase 2 study results showed significant improvements in PTSD symptoms, with a notable CAPS-5 score reduction, indicating the potential efficacy of TSND-201.

How is TSND-201 administered?

In the trial, TSND-201 was administered as four oral doses, each separated by a week, to evaluate its effects on PTSD symptoms over 64 days.

What safety profile does TSND-201 have?

TSND-201 demonstrated a favorable safety profile, with most adverse effects being mild and transient in nature, aligning with its design as a non-hallucinogenic treatment.

What are the future plans for TSND-201?

Transcend Therapeutics plans to collaborate with the FDA on a Phase 3 program to further assess the efficacy and safety of TSND-201 in treating PTSD.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 7

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 6

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 3

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 3

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 3

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 5

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading

Top 5 Most Recently Viewed Articles

Retractable Technologies Announces Dividend Distribution for Shareholders

Updated Category News Views 73

Retractable Technologies, Inc. (NYSE American: RVP) made headlines back in 2024 when it declared dividends to its Series II Class B and Series III Class B Convertible Preferred Stock holders. The total amount? A neat $39,050 for one class and $18,561.25 for the other—about $57,611 in total. Now that’s a number that should catch the eye of any savvy investor....

Continue Reading
Northfield Capital Shares Split Announced with Juno Corp Update

Updated Category News Views 269

Exciting Developments from Northfield Capital Corporation Northfield Capital Corporation (TSX-V: NFD.A) is making waves with exciting updates on its cornerstone investment, Juno Corp., a notable player in the strategic Ring of Fire region. Juno Corp. has recently released encouraging results from its latest drilling campaign, amplifying the prospects of Northfield’s...

Continue Reading
Understanding the P/E Ratio: A Guide for Investors

Updated Category News Views 116

Analyzing the Price-to-Earnings Ratio of Applied Materials In today's trading session, Applied Mat Inc. (NASDAQ: AMAT) shares are currently valued at $184.34, marking a notable increase of 0.62%. When reflecting on the past month, this stock has seen an impressive rise of 13.97%. However, from a yearly perspective, the shares have experienced a decline of 23.47%....

Continue Reading
Unveiling the Truth: Impact of 'Saving PTK' on Honor Societies

Updated Category News Views 698

Unpacking the Revelations in 'Saving PTK' Saving PTK: The Whistleblower's Fight for Truth and Change by Toni Marek delves deep into the complexities and challenges surrounding Phi Theta Kappa (PTK), the largest honor society in the United States for community college students. The book addresses various systemic issues within PTK identified by Marek, who emerged as a...

Continue Reading
Kyra Rénel Hardwick Celebrated as Outstanding Entrepreneurial Leader

Updated Category News Views 115

Kyra Rénel Hardwick Wins 2024 Entrepreneurial Women of Impact Award Kyra Rénel Hardwick, a well-known leader in the business realm, has been honored as one of the recipients of the 2024 Entrepreneurial Women of Impact Awards. This esteemed recognition was given to her by the Women Presidents Organization in partnership with Women Elevating Women, celebrating her...

Continue Reading